

Anthrax vaccine approval expanded

November 24 2015

(HealthDay)—U.S. Food and Drug Administration approval for the BioThrax anthrax vaccine has been expanded to include adults aged 18 to 65 with known or suspected exposure, the agency said in a media release.

The [vaccine](#) was first approved in 1970 for people at [high risk](#) of anthrax contact.

Exposure to *Bacillus anthracis* bacteria, especially if inhaled, can cause death if not promptly treated. Anthrax is considered a potential bioterrorism weapon, since it is easy to disperse and is relatively hearty, the agency said. Exposure also is possible by contact with an infected animal or animal products.

Expanded approval for the [injected vaccine](#) was granted under the agency's "animal rule," which states [animals](#) may be used to test a drug or product for purposes that aren't ethical or feasible among people, the FDA said.

The BioThrax vaccine was tested on exposed rabbits and deemed to provide a "reasonable level of protection," by providing a survival rate of 70 percent to 100 percent, the agency said.

Adverse reactions among people who have been given the vaccine for pre-disease prevention have included tenderness, pain, swelling, injection-site redness, muscle aches, headache and fatigue.

BioThrax is produced by Michigan-based Emergent BioDefense Operations Lansing LLC.

More information: To learn more about this approval, visit the [FDA](#).

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Anthrax vaccine approval expanded (2015, November 24) retrieved 26 April 2024 from <https://medicalxpress.com/news/2015-11-anthrax-vaccine.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--